trending Market Intelligence /marketintelligence/en/news-insights/trending/lLRpxIvm1b8QMNtsoWGMIQ2 content esgSubNav
In This List

Proteostasis plans common stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Proteostasis plans common stock offering

Proteostasis Therapeutics Inc. plans to offer 7 million common shares in an underwritten public offering.

The company also plans to grant underwriters a 30-day option to buy up to an additional 1,050,000 shares, or up to 15% of the offering size.

Leerink Partners LLC and RBC Capital Markets LLC are acting as joint book-running managers for the offering, with H.C. Wainwright & Co. LLC as lead manager.